Educational Course on Dermatological Diseases

The Goal

The goal of the dermatology interactive course is to provide the latest views on the use of Extracorporeal Photopheresis in dermatological diseases and foster discussion between peers.

Agenda

Download Agenda PDF

Day 1 - 19 March 2024

Arrival of participants

20:00 – 20:15
Meeting at hotel lobby

20:15
Dinner with the faculty

Day 2 - 20 March 2024

09:00 – 09:45
Welcome and Extracorporeal Photopheresis overview - Prof Robert Knobler

09:45 – 10:15
Cutaneous T-cell Lymphoma pathophysiology - Prof Emmanuella Guenova

10:15 – 10:45
Proposed Extracorporeal Photopheresis Mechanism of Action in Cutaneous T-cell Lymphoma - Prof Emmanuella Guenova

10:45 – 11:00
Interactive discussion

11:00 – 11:15
Coffee break

11:15 – 11:45
Extracorporeal Photopheresis for Cutaneous T-cell Lymphoma: evidence, guidelines and Time to Next Treatment as a novel tool to measure response - Prof Julia Scarisbrick

11:45 – 12:00
Interactive discussion and Cutaneous T-cell Lymphoma case reports

12:00 – 12:45
Lunch

12:45 – 13:15
Extracorporeal Photopheresis beyond Cutaneous T-cell Lymphoma - Prof Emmanuella Guenova

13:15 – 13:45
Extracorporeal Photopheresis in systemic sclerosis - Prof Robert Knobler

13:45 – 14:15
Skin Graft versus Host Disease - Prof Hildegard Greinix

14:15 – 14:45
Break

14:45 – 14:55
Interactive discussion and patient cases beyond Cutaneous T-cell Lymphoma

14:55 – 15:15
Vienna experiences - Prof Robert Knobler

15:15 – 15:30
Final remarks and close

For this course, participants are required to submit one patient case for discussion 15 days in advance of the session

All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals
This information is not intended for healthcare professionals based in the US and Canada.

Hosted by

Prof Robert Knobler

Associate Professor of Dermatology, Department of Dermatology, Division for Special & Environmental Dermatology, Medical University of Vienna

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease.
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³.
Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOS^TM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS^TM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

Please refer to the THERAKOS^TM CELLEX^TM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOS^TM CELLEX^TMPhotopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.